HeartBeam (BEAT) Q2 2026 earnings review
Clinical Milestones Hit, But Unannounced CEO Departure Raises Questions
HeartBeam continues to execute on its clinical timeline, completing enrollment in its ALIGN-ACS heart attack detection pilot ahead of schedule and initiating a pilot for its 12-lead extended wear patch. As a pre-revenue company, cash preservation is paramount: management successfully lowered its FY26 operating cash outflow guidance to below $14.0 million. However, a major red flag emerged buried in the financials: a sudden C-suite shakeup. SG&A spiked due to severance and accelerated equity for the 'former CEO' (Rob Eno), with Founder Branislav Vajdic taking over as Principal Executive Officer right as the critical initial commercial launch gets underway.
🐂 Bull Case
The ALIGN-ACS pilot enrolled 134 patients in under four months, beating Q3 targets. Results at TCT 2026 will serve as a major catalyst for FDA pivotal study design.
The company reduced operating cash burn by 7% sequentially and lowered full-year outflow guidance, successfully extending its cash runway further into 2027 following the April $11.5M capital raise.
🐻 Bear Case
The abrupt and unannounced departure of CEO Rob Eno during the critical early stages of commercial rollout introduces significant execution risk.
Despite the recent capital raise, HeartBeam ended Q2 with just $8.8M in total cash. Without immediate and meaningful revenue generation, another dilutive equity raise will be necessary within 12 months.
⚖️ Verdict: ⚪
Neutral. The underlying technology platform is advancing well, particularly the clinical trial velocity. However, a stealthy CEO departure during early commercialization combined with a still-fragile balance sheet offsets the operational wins.
Key Themes
Clinical Trial Momentum & Indication Expansion
HeartBeam is moving aggressively to expand indications beyond arrhythmia. The ALIGN-ACS pilot study (evaluating heart attack detection) completed enrollment of 134 patients ahead of schedule. Data analysis is underway with a full readout planned for TCT 2026 in Q4. Simultaneously, the Indonesian-backed HEADSTART-ACS study surpassed 50% enrollment in under three months. These rapid readouts are crucial for defining the FDA pathway for the massive 20-million patient myocardial infarction market.
12-Lead Patch Advances to Clinical Phase
The company officially completed a working prototype of its 12-lead ECG extended-wear patch and initiated a 50-patient pilot study for ischemia detection in Serbia. By combining continuous single-lead monitoring with on-demand 12-lead capabilities, HeartBeam is positioning itself to disrupt the $2 billion ambulatory cardiac monitoring market currently dominated by traditional Holter monitors and basic patch competitors.
Commercial Launch Transitions from Setup to Shipping
Following anchor account signings in Q1, HeartBeam shipped its first commercial orders and onboarded initial patients in Q2. Management notes that orders of 'increasing magnitude' are occurring in Q3. The company is strategically embedding HeartBeam directly into new patient intake workflows at concierge practices, which should accelerate the path to the 30,000-patient breakeven target.
Unannounced C-Suite Departure During Commercial Ramp
Buried in the SG&A expense explanation is a massive red flag: $0.9 million in severance and accelerated stock-based compensation for the 'former CEO' (Rob Eno). Founder Branislav Vajdic has stepped back into the Principal Executive Officer role as of July 1. Changing CEOs exactly as the company shifts from R&D to commercialization often signals internal friction or early sales struggles, and the lack of a dedicated press release for the transition is concerning.
Cash Runway Leaves Little Margin for Error
While cash burn guidance was lowered, the balance sheet remains extremely tight. The company ended Q2 with $8.8 million in cash. Even if they hit their Q4 target of <$2.5M in quarterly cash outflow, the current balance only provides roughly three to four quarters of clean runway, reinforcing management's projection that it extends 'into 2027'. Revenue must ramp aggressively in H2 2026 to avoid further dilutive financing.
R&D Spending Decelerating Ahead of Pivotal Trials
R&D expenses fell from $3.3M in Q2 2025 to $2.3M in Q2 2026, primarily due to lower consulting and product development costs for the core system. While this aids cash preservation, investors must monitor whether this lean spending model will support the impending U.S. pivotal study for heart attack detection, which will be significantly more expensive than the current pilot studies.
Other KPIs
Stable YoY. While R&D expenses fell by $1.0 million, SG&A increased by $1.1 million, largely driven by $0.9 million in non-recurring severance and stock-based compensation for the departing CEO.
Up from $4.4 million at year-end 2025, benefiting entirely from the April 2026 $11.5 million public offering. The company continues to operate with a precarious balance sheet relative to its clinical ambitions.
Guidance
Accelerating optimization. This is a reduction from the prior quarter's updated guidance of 'below $16.0 million' (and original guidance of $17-$19 million). It reflects strict cost control and a leaner-than-planned commercial hiring footprint.
Stable. The company expects elevated near-term costs due to the short-term impact of restructuring the cost profile and executive severance.
Decelerating burn. Management expects a structural step-down in baseline expenses, aided further by incoming cash receipts from early commercial customer contracts.
Key Questions
CEO Departure Context
What were the specific drivers behind Rob Eno's departure just as commercialization is beginning, and is Branislav Vajdic taking the role permanently or is an executive search underway?
Commercial Revenue Trajectory
With initial orders now shipping, what is the expected cash flow contribution from commercial operations in H2 2026, and how many practices are currently live?
Patch Partnership Timeline
Now that a working prototype is complete and a pilot study is underway, what is the timeline for securing a strategic commercial partner for the 12-lead patch?
Pivotal Trial Capitalization
Assuming positive ALIGN-ACS data at TCT 2026, how does management intend to fund the upcoming U.S. FDA pivotal study given the current $8.8 million cash balance?